Literature DB >> 24731430

Influence of antimicrobial regimen on decreased in-hospital mortality of patients with MRSA bacteremia.

Norihito Kaku1, Katsunori Yanagihara2, Yoshitomo Morinaga1, Koichi Yamada3, Yosuke Harada1, Yohei Migiyama1, Kentaro Nagaoka1, Jun-Ichi Matsuda4, Naoki Uno4, Hiroo Hasegawa4, Taiga Miyazaki3, Koichi Izumikawa3, Hiroshi Kakeya3, Yoshihiro Yamamoto3, Shigeru Kohno3.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most important causes of bacteremia. Recently, several epidemiological and microbiological changes have become evident in MRSA infections. The purposes of this study were to assess clinical characteristics of patients with MRSA bacteremia and microbiological changes in MRSA. We conducted a retrospective observational study on patients with MRSA bacteremia who were hospitalized between 2008 and 2011. We used univariate and multivariate analysis to evaluate the predictors associated with 30-day mortality. The 7-day and 30-day mortality rates were 12.0% and 25.3%, respectively. According to multivariate analysis, the independent predictors that associated with 30-day mortality were leukopenia, low serum albumin, high sequential organ failure assessment (SOFA) score, and quinolone use within 30 days. Compared to previous data (2003-2007), the SOFA score of the new data set remained unchanged, but in-hospital mortality decreased significantly. In particular, the mortality associated with use of vancomycin (VCM) was significantly lower. Although the minimum inhibitory concentration of VCM required to inhibit the growth of 90% of organisms (MIC90) had not changed, the trough value of VCM changed significantly; a VCM trough value of 10 or greater was significantly higher compared to previous data. Of the staphylococcal cassette chromosome mec (SCCmec) types, SCCmec II values decreased significantly, and SCCmec I and IV values increased significantly. Our results indicate that changes in VCM usage might contribute to decreased in-hospital mortality.
Copyright © 2014 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bacteremia; MIC; Methicillin-resistant Staphylococcus aureus; Mortality; SCCmec

Mesh:

Substances:

Year:  2014        PMID: 24731430     DOI: 10.1016/j.jiac.2013.12.009

Source DB:  PubMed          Journal:  J Infect Chemother        ISSN: 1341-321X            Impact factor:   2.211


  6 in total

1.  The use of vancomycin in the treatment of adult patients with methicillin-resistant Staphylococcus aureus (MRSA) infection: a survey in a tertiary hospital in China.

Authors:  Jing Tang; Jiali Hu; Lei Kang; Zhengjun Deng; Jiaofen Wu; Jiaqian Pan
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  In vitro bactericidal activity of 4- and 5-chloro-2-hydroxy-N-[1-oxo-1-(phenylamino)alkan-2-yl]benzamides against MRSA.

Authors:  Iveta Zadrazilova; Sarka Pospisilova; Karel Pauk; Ales Imramovsky; Jarmila Vinsova; Alois Cizek; Josef Jampilek
Journal:  Biomed Res Int       Date:  2015-01-15       Impact factor: 3.411

3.  Tedizolid Phosphate: a Next-Generation Oxazolidinone.

Authors:  Jeffrey M Rybak; Karrine Roberts
Journal:  Infect Dis Ther       Date:  2015-02-24

4.  Adherence rate of quality-of-care indicators for Staphylococcus aureus bacteremia is extremely low in Japanese emergency and critical care departments: a multicenter retrospective observational study.

Authors:  Kyohei Miyamoto; Seiya Kato; Junichi Kitayama; Junpei Okawa; Ayana Okamoto; Jun Kamei; Kazuhisa Yoshiya; Hideki Asai; Shingo Adachi; Hidekazu Yukioka; Hiroshi Akimoto; Kazuo Okuchi
Journal:  Acute Med Surg       Date:  2017-10-25

5.  Clinical Characteristics of Methicillin-resistant Coagulase-negative Staphylococcal Bacteremia in a Tertiary Hospital.

Authors:  Koichi Yamada; Hiroki Namikawa; Hiroki Fujimoto; Kiyotaka Nakaie; Etsuko Takizawa; Yasuyo Okada; Akiko Fujita; Hiroyoshi Kawaguchi; Yasutaka Nakamura; Junko Abe; Yukihiro Kaneko; Hiroshi Kakeya
Journal:  Intern Med       Date:  2017-04-01       Impact factor: 1.271

6.  Antibacterial Activity of a Promising Antibacterial Agent: 22-(4-(2-(4-Nitrophenyl-piperazin-1-yl)-acetyl)-piperazin-1-yl)-22-deoxypleuromutilin.

Authors:  Xiang-Yi Zuo; Hong Gao; Mei-Ling Gao; Zhen Jin; You-Zhi Tang
Journal:  Molecules       Date:  2021-06-08       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.